Amorfix provides update on ALS diagnostic program

TORONTO, Jan. 22, 2013 /CNW/ - Amorfix Life Sciences Ltd. announced that it 
has completed initial steps in the generation of a blood test for the 
diagnosis of ALS. Using a proprietary antibody in a simple ELISA assay, the 
Company is able to detect and measure misfolded superoxide dismutase 1 (SOD1) 
added into human plasma. Misfolded SOD1 is thought to have an important role 
in the pathogenesis of both familial and sporadic ALS. 
The Company initiated this project based on results from a ground breaking 
scientific study conducted by Amorfix Chief Scientific Officer Dr. Neil 
Cashman and colleagues at UBC demonstrating that misfolded SOD1 is present in 
the blood of ALS patients. The initial scientific discovery was achieved using 
a technique that is not amenable for use as a screening test, but clearly 
established the proof of concept for the presence of misfolded SOD1 in the 
blood of ALS patients. The Company has now taken important first steps towards 
developing a test that can be easily used by clinicians to rule in or out a 
diagnosis of ALS. 
There is a high unmet medical need for such a test. At the present time, 
clinicians must rely on a combination of clinical findings and indirect 
testing to confirm a diagnosis of ALS, as there is no diagnostic test or 
biomarker at their disposal. The Company believes that the availability of a 
reliable blood test would represent an important advancement in the management 
of this devastating disease, allowing clinicians to diagnose the disease 
earlier and provide better treatment. The projected market for such a 
diagnostic test is approximately $250M. 
"We are fully exploiting our dominant intellectual property position for 
misfolded SOD1" said Dr. Robert Gundel, Amorfix President and Chief Executive 
Officer. "We are using our proprietary antibodies for the development of 
therapeutic antibodies, through a license agreement with Biogen-Idec, for the 
development of therapeutic vaccines, through a license agreement with PREVENT, 
and for the development of a blood test for the early diagnosis and treatment 
of ALS. The recent data for the ALS blood test represent a significant 
advancement in the development of a valuable asset for the company." 
About ALS 
ALS is a common neuromuscular disease, affecting an estimated 120,000 people 
of all races and ethnic backgrounds worldwide. According to the ALS 
Association, more than 5,600 people in the U.S. are diagnosed with ALS 
annually and an estimated 30,000 Americans have ALS at any given time. 
About Amorfix 
Amorfix Life Sciences Ltd. (TSX: AMF) is an early-stage product development 
company developing therapeutic antibodies and diagnostics targeting misfolded 
protein diseases. Amorfix utilizes its computational discovery platform, 
ProMIS™, to predict novel Disease Specific Epitopes (DSEs) on the molecular 
surface of misfolded proteins. Using this technology, Amorfix is developing 
novel antibody therapeutics and companion diagnostics for cancer and 
amyotrophic lateral sclerosis (ALS). In addition, Amorfix has developed two 
proprietary technologies to specifically identify very low levels of misfolded 
proteins in a biological sample: Epitope Protection™ and AMFIA™, an 
ultra-sensitive dual-bead immunoassay. Use of these technologies has generated 
a cerebrospinal fluid (CSF) screening test for both Alzheimer's disease (AD) 
and mild cognitive impairment (MCI), and an ultrasensitive method for 
detecting the hallmark of AD, aggregated beta-Amyloid, in brain tissue, CSF 
and blood from animal models of AD. For more information about Amorfix, visit 
The TSX has not reviewed and does not accept responsibility for the adequacy 
or accuracy of this release. This information release may contain certain 
forward-looking information. Such information involves known and unknown 
risks, uncertainties and other factors that may cause actual results, 
performance or achievements to be materially different from those implied by 
statements herein, and therefore these statements should not be read as 
guarantees of future performance or results. All forward-looking statements 
are based on the Company's current beliefs as well as assumptions made by and 
information currently available to it as well as other factors. Readers are 
cautioned not to place undue reliance on these forward-looking statements, 
which speak only as of the date of this press release. Due to risks and 
uncertainties, including the risks and uncertainties identified by the Company 
in its public securities filings, actual events may differ materially from 
current expectations. The Company disclaims any intention or obligation to 
update or revise any forward-looking statements, whether as a result of new 
information, future events or otherwise, unless required by law. 
ProMIS™, Epitope Protection™ and AMFIA™ are trademarks of Amorfix Life 
Sciences Ltd. 
Dr. Robert Gundel President and Chief Executive Officer Amorfix Life Sciences 
Ltd. Tel: (416) 847-6957 Fax: (416) 847-6899  
Janet Clennett Acting Chief Financial Officer Amorfix Life Sciences Ltd. Tel: 
(416) 847-6926 Fax: (416) 847-6899  
SOURCE: Amorfix Life Sciences Ltd. 
To view this news release in HTML formatting, please use the following URL: 
CO: Amorfix Life Sciences Ltd.
ST: Ontario
Press spacebar to pause and continue. Press esc to stop.